tbuckley/cabot-search huggingface dataset:
Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes
Authors: Clare B. Kelly, Michelle B. Hookham, Jeremy Y. Yu, Alicia J. Jenkins, Alison J. Nankervis, Kristian F. Hanssen, Satish K. Garg, James A. Scardo, Samar M. Hammad, M. Kathryn Menard, Christopher E. Aston, Timothy J. Lyons
Journal: Diabetes Care (2017)

OBJECTIVE This study was conducted to determine the utility of tubular (urinary/plasma neutrophil gelatinase-associated lipocalin [NGAL] and urinary kidney injury molecule 1 [KIM-1]) and glomerular (estimated glomerular filtration rate [eGFR]) biomarkers in predicting preeclampsia (PE) in pregnant women with type 1 diabetes mellitus (T1DM) who were free of microalbuminuria and hypertension at the first trimester. RESEARCH DESIGN AND METHODS This was a prospective study of T1DM pregnancy. Maternal urinary and plasma NGAL, urinary KIM-1 (ELISA of frozen samples), and eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) were determined at three study visits (V1: 12.4 ± 1.8; V2: 21.7 ± 1.4; V3: 31.4 ± 1.5 weeks’ gestation [mean ± SD]) in 23 women with T1DM with subsequent PE (DM+PE+), 24 who remained normotensive (DM+PE−), and, for reference, in 19 normotensive pregnant women without diabetes (DM−). The groups with diabetes were matched for age, diabetes duration, and parity. All subjects were normotensive and free of microalbuminuria or albuminuria at V1. All study visits preceded the onset of PE. RESULTS Urinary creatinine-corrected NGAL (uNGALcc, ng/mg) was significantly elevated at V1 in DM+PE+ vs. DM+PE− women (P = 0.01); this remained significant after exclusion of leukocyte-positive samples (5 DM+PE+ and 2 DM+PE−) (P = 0.02). Accounting for BMI, HbA1c, and total daily insulin dose, a doubling of uNGALcc at V1 conferred a sevenfold increase in risk for PE (P = 0.026). In contrast, neither plasma NGAL nor urinary KIM-1 predicted PE. Also at V1, eGFR was elevated in DM+PE+ vs. DM+PE− (P = 0.04). CONCLUSIONS Early tubular and glomerular dysfunction may predict PE in first trimester women with T1DM, even if free of microalbuminuria. These data suggest that subclinical renal tubular and glomerular injury, if present early in pregnancy, may predispose women with T1DM to PE.
ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)
Authors: David Reardon, Thomas Kaley, Jorg Dietrich, Jennifer L Clarke, Gavin P Dunn, Michael Lim, Timothy Cloughesy, Hui K Gan, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus
Journal: Neuro-Oncology (2017)

GBM patients who progress on BEV, an approved angiogenesis inhibitor for recurrent GBM, have a dismal outcome with a median survival of < 6 months. DUR is a human IgG1 monoclonal Ab against PD-L1. This ongoing Phase 2 open-label study (NCT02336165) evaluates safety and efficacy of DUR (10 mg/kg every 2 weeks [Q2W]) in 5 GBM cohorts. Results are presented for Cohort C (DUR + continuing BEV 10 mg/kg Q2W in BEV-refractory recurrent GBM). The primary efficacy endpoint for Cohort C is overall survival at 6 months (OS-6), based on modified RANO criteria by investigator assessment; secondary endpoints include safety/tolerability and progression-free survival (PFS). The Intent-to-treat population includes patients receiving any dose of DUR and having at least baseline and 1 post-baseline tumor assessment. First patient treated: 24 Mar 2015; data cutoff: 15 Mar 2017. Cohort C completed enrollment of 22 patients (male: 63.6%; mean age: 54.8 [37–77] years; baseline ECOG PS0: 27.3%, PS1: 68.2%; baseline measurable lesions: 81.8%). Treatment-emergent adverse events (TEAEs) occurred in 19 (86.4%) patients and most commonly included neurologic events associated with GBM. Treatment-related AEs (TRAEs) occurred in 10 (45.5%) patients, and incidences by maximum CTCAE grade (Gr) were Gr1: 5 (22.7%); Gr2: 4 (18.2%); Gr3: 1 (4.5%; fatigue); and Gr4/5: 0 patients. Most common TRAEs (≥2 [9.1%] patients) were fatigue, increased ALT, constipation, and headache. All patients (n=22) were evaluable for efficacy: OS range, 0.9 - 51.6 weeks; 8 patients (36%) had OS ≥ 22 weeks; PFS range, 0.9 -24.4 weeks; 11 patients (50%) had PFS ≥ 8 weeks; 3 patients were still alive at cutoff date; OS-6 to follow. DUR + continuing BEV therapy appears to be well tolerated and shows preliminary activity in BEV-refractory recurrent GBM. Further studies are warranted.
P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Authors: R. Pillai, S. Ramalingam, L. Paz-Ares, M. Thayu, P. Watson, M. Reck
Journal: Journal of Thoracic Oncology (2017)
P2.02-021 Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients
Authors: S. Wang, C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, R. Chen, Y. Guan, X. Yi, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
TMIC-46. TUNING OF HYPOXIC AND PSEUDO-HYPOXIC GLIOMA PHENOTYPES IN PERIVASCULAR AND PERINECROTIC NICHES
Authors: Elinn Johansson, Elisa Grassi, Vasiliki Pantazopoulou, Bei Tong, David Lindgren, Tracy Berg, Håkan Axelson, Alexander Pietras
Journal: Neuro-Oncology (2017)

Stem-like glioma cells have been proposed to reside in hypoxic and/or perivascular tumor niches. Such cells display an amplified cellular response to hypoxia, and appear to have a pseudo-hypoxic phenotype both at normoxia in vitro, and in a well-oxygenated perivascular niche in vivo. Hypoxia-inducible factors are central to maintaining several properties of stem cells, but little is known about differential HIF regulation in stem vs. bulk glioma cells. Using mouse models of high-grade glioma, together with primary cultures of human glioma cells, we have identified novel cell surface regulators of hypoxic and pseudo-hypoxic phenotypes in glioma, with differential expression in stem vs. bulk glioma cells. Gamma-secretase dependent release of the intracellular domains (ICDs) of both CD44 and p75NTR was enhanced at hypoxia, and signaling from these ICDs differentially regulated HIF-1alpha and HIF-2alpha to tune the hypoxic and pseudo-hypoxic glioma phenotype independently of oxygen tension. Forced expression of the CD44 and p75NTR ICDs was sufficient to induce hypoxia signaling at oxygen tensions relevant to the perivascular niche, and inhibition of ICD release was sufficient to block hypoxia-induced stem cell characteristics of cultured glioma cells. Together, our data indicate that some markers of stem-like cells can actively contribute to the stem cell character of perivascular and perinecrotic glioma cells, by modulating the cellular response to hypoxia.
P1.14-011 An Esophagus-Sparing Technique to Limit Radiation Esophagitis in Locally Advanced NSCLC Treated by SIB-IMRT and Concurrent Chemotherapy
Authors: H. Liu, L. Ma, Q. Li, L. Chen, M. Lin, B. Wang, Y. Hu, M. Liu, L. Zhang, Y. Huang, X. Deng, Y. Xia, B. Qiu
Journal: Journal of Thoracic Oncology (2017)
P1.13-002 New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype
Authors: Y. Sawai, J. Nitadori, T. Takahashi, K. Kitano, K. Nagayama, M. Anraku, M. Sato, J. Nakajima
Journal: Journal of Thoracic Oncology (2017)
ATIM-07. STUDY OF PEMBROLIZUMAB, TUMOR TREATMENT FIELDS (OPTUNE®) AND TEMOZOLOMIDE FOR OLDER SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Laura Donovan, David Cieremans, Teri Kreisl, Mary Welch, Andrew B Lassman, Fabio Iwamoto
Journal: Neuro-Oncology (2017)

Given the median age of diagnosis in glioblastoma is 65 years, a sizable proportion of cases occur in the elderly population. One of the most feared complications of radiation in elderly patients is cognitive decline due to radiation-induced neurotoxicity, which can be irreversible, extremely debilitating and often progressive. Brandes et al. reported a worsening of neurologic status in 56% of 58 elderly patients 65 years of age or older treated with standard chemoradiation. In the elderly patient population, the use of radiation therapy can bring excessive toxicity, while the use of temozolomide alone leads to limited durability of efficacy. The addition of pembrolizumab and Optune® might lead to prolonged survival without the need for upfront radiation therapy. Eligible participants include patients with newly-diagnosed glioblastoma age ≥ 65 years. This ongoing trial uses Optune® continuously starting as soon as 4 weeks from surgery and continuing for up to 24 months. Temozolomide 150–200 mg/m2/day is dosed for 5 days every 28 days for up to 12 cycles and pembrolizumab 200 mg is dosed every 3 weeks for up to 24 months. The primary efficacy objective of this trial is to evaluate the potential anti-tumor activity of pembrolizumab in combination with Optune® and temozolomide in newly diagnosed glioblastoma patients ≥ 65 years old. We will measure the percentage of patients who are alive at 12 months (OS12). Based on historical data showing an overall survival at 1-year of 20% in older glioblastoma patients, we set H0=20% and H1=45%. With 22 evaluable patients and a one-sided α of 0.05, the exact power is 85%. If at least 8 of 22 evaluable patients are alive at 1-year, this regimen will be considered for further study. Progression-free survival, objective response rate and duration of response for patients with measurable tumor will also be evaluated.
OA 18.01 Paired Tumor-Normal Next-Generation Sequencing (NGS) to Identify Pathogenic / Likely Pathogenic Germline Mutations in Lung Cancer Patients
Authors: Y. Yi, R. Chen, P. Dai, C. Zhu, J. Huan, T. Liu, M. Zhao, Y. Guan, L. Yang, X. Xia, X. Yi
Journal: Journal of Thoracic Oncology (2017)
MA 09.06 Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy (SBRT): A Nationwide Survey of 1,378 Patients
Authors: Y. Niibe, T. Yamamoto, H. Onishi, H. Yamashita, K. Katsui, Y. Matsumoto, R. Oh, M. Aoki, T. Shintani, M. Myojin, K. Yamada, M. Kobayashi, M. Ozaki, Y. Manabe, K. Yahara, A. Nishikawa, H. Kakuhara, Y. Matsuoka, K. Yamamoto, T. Fukuda, Y. Ushijima, S. Ohashi, T. Kan, S. Kubota, T. Inoue, N. Yamaguchi, Y. Takada, K. Nagata, O. Suzuki, K. Shirai, A. Terahara, K. Jingu
Journal: Journal of Thoracic Oncology (2017)
P3.15-001 The Impact of MET Inhibition on Small-Cell Lung Cancer Cells Exhibiting Aberrant Activation of the HGF/MET Pathway
Authors: H. Taniguchi, T. Yamada, S. Takeuchi, S. Arai, K. Fukuda, S. Sakamoto, M. Kawada, H. Yamaguchi, H. Mukae, S. Yano
Journal: Journal of Thoracic Oncology (2017)
PDTM-16. IDENTIFICATION OF NOVEL EPIGENETIC DRUG COMBINATIONS WITH SYNERGISTIC INHIBITORY EFFECTS AGAINST MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
Authors: Lei Zhang, Meng Li, Yi Sui, Fang Liu, Wenyan Jiang, Tiantian Li, Yujie Tang
Journal: Neuro-Oncology (2017)

Medulloblastoma is the most common type of malignant pediatric brain tumor. It can be categorized into 4 major subgroups with distinct biological and clinical signatures: WNT, SHH, Group 3 and Group 4. MYC-amplified Group 3 medulloblastoma tend to metastasis and have the worst prognosis, however, they have been recently shown to be effectively inhibited by epigenetic drugs such as BET inhibitor and HDAC inhibitor in preclinical studies, suggesting epigenetic drug could serve as novel and promising therapeutic strategy for them. Based on these previous findings, we performed epigenetic drug combination screening by using patient derived MYC-amplified Group 3 medulloblastoma primary cell lines based on BET inhibitor JQ1 and HDAC inhibitor panobinostat, and identified some drug combinations with potential synergistic inhibitory effects. Further tests on cell viability, proliferation and apoptosis have validated the synergy of some of our identified epigenetic drug combinations. Currently we are testing their combinatory treatment by using in vivo mouse and human MYC-amplified Group 3 medulloblastoma tumor models. RNA-seq and ChIP-seq analyses will also be performed to dissect the underlying molecular mechanism of our identified epigenetic drug combinations. Our study will provide preclinical efficacy and molecular mechanism of novel epigenetic drug combinations with synergistic inhibitory effects against MYC-amplified Group 3 medulloblastoma.
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)
Authors: S. Gori, M. Turazza, A. Inno, G. Lunardi, S. Moroso, N. La Verde, A. Frassoldai, E. Tarenzi, O. Garrone, P. Vici, L. Laudadio, E. Cretella, J. Foglietta, V. Leonardi, L. Cavanna, S. Barni, F. Marchetti, M. Valerio, G. Carbognin, F. Alongi, A. Fabi
Journal: Annals of Oncology (2017)
Mortality and health-related habits in 900 Finnish former elite athletes and their brothers
Authors: Titta Katariina Kontro, Seppo Sarna, Jaakko Kaprio, Urho M Kujala
Journal: British Journal of Sports Medicine (2017)

Background There is conflicting evidence on the associations between participation in vigorous sports, health habits, familial factors and subsequent mortality. We investigated all-cause mortality and health-related behaviour among former elite athletes and their brothers. Methods The mortality of Finnish male former elite athletes, who had represented Finland between 1920 and 1965 (n=900) and their age-matched brothers (n=900), was followed from the time when athlete started an elite athlete career until 31 December 2015. The age-adjusted HRs were calculated by a paired Cox proportional hazards model. In 2001, surviving participants (n=199 athletes and n=199 age-matched brothers) reported their self-rated health (SRH), physical activity, alcohol consumption and smoking habits in the questionnaire. Results During the total follow-up period, 1296 deaths (72% of the cohort) occurred. The age-adjusted HRs for all-cause mortality in former athletes was 0.75 (95% CI 0.65 to 0.87, P&lt;0.001) compared with their age-matched brothers. Median age at death was 79.9 years for endurance, 75.9 years for mixed sports and 72.2 years for power sports athletes, and 77.5, 73.7 and 72.2 years for their age-matched brothers, respectively. In 2001, compared with their brothers, former athletes smoked less (P&lt;0.001), were more physically active (P&lt;0.05) and rated their health more often as very good (P&lt;0.05). Conclusions Former elite athletes are more physically active, smoke less, have better self-rated health and live longer than their brothers. Genetic differences between athletes and brothers, aerobic training for endurance elite sports and a healthier lifestyle may all contribute to reduced mortality.
ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS
Authors: Jan Drappatz, Frank Lieberman, Melinda Vargas-Jaffe, Daniel Normolle, Christopher Moertel, Lisa H Butterfield, Hideho Okada
Journal: Neuro-Oncology (2017)

We conducted a pilot study of intradermal vaccinations with tumor lysate and imiquimod in adults with newly diagnosed high-risk low-grade glioma (LGG). The vaccine uses the brain tumor initiating cell (BTIC) cell line GBM6-AD as antigen source. GBM6-AD expresses glioma-associated antigens (GAAs), including interleukin-13 receptor (IL- 13R)α2, EphA2, and Her-2 and key BTIC antigens, including CD133, nestin, and Sox-2. Patients were enrolled into three cohorts: LGG without prior therapy (Cohort 1); LGG with stable disease following chemo and /or radiation therapy (Cohort 2); or recurrent LGG (Cohort 3). Vaccinations were administered on weeks 0, 3, 9, 15 and 21 and every 16 weeks for up to 2 years. Imiquimod was applied topically prior to vaccination and at 24 hours. Primary endpoints were safety and CD8+ T-cell responses against vaccine targeted GAAs in post-vaccine PBMC using IFN-γ- ELISPOT. Exploratory endpoints were response and progression free survival (PFS). Cohorts 1, 2, and 3 enrolled 6, 11, and 2 patients, respectively. No regimen-limiting toxicity has been encountered. One patient died due to an accidental opioid overdose. There were one grade 4 lipase, and grade 3 AST and ALT elevation. Gr 1/2 fatigue was the most common AE in 7 patients. Other at least possibly related AE’s (all grade 1) include seizure (3), injection site reaction (3), headache (2), decreased ANC (2) and one event of nausea, abdominal pain, fever and flu-like symptoms each. Best response was stable disease (n=18). Median PFS was 23.5 months (Cohort 1; since diagnosis; range 8–54 months) and 14 months (Cohort 3; since the 1st vaccine; range 8–28 months) and 14 months in cohort 3 (range 10–18 months). Sixteen patients are alive to date. The vaccine was well tolerated. Immunological and updated survival data will be presented. A larger efficacy study is warranted.
Abstract 16564: EVGATA-4 Promoted Angiogenesis Through Delivering miRNAs to Endothelial Cells
Authors: Min Gong, Bin Yu, Yuping Duan, Yi-gang Wang, Muhammad Ashraf, Meifeng Xu
Journal: Circulation (2016)

Recently, we have shown that extracellular vesicles (EVs) produced by GATA-4-overexpressing mesenchymal stem cell (MSCs) (EV GATA-4 ) significantly improved ischemic myocardial function, compared to EVs from vector-empty transfected MSCs (EV null ). We hypothesized that EV GATA-4  promoted angiogenesis in ischemic myocardium via miRs released in recipient cells. MSCs were transduced with GATA-4 using the murine stem cell virus retroviral expression system and EVs were harvested from the conditioned media of MSC GATA-4  and its control counterpart MSC null . The tubular structures formation of human umbilical vein endothelial cells (HUVECs) and Matrigel plug were used to evaluate angiogenesis. The data of MicroRNA-seq showed that 358 miRs were found in EVs, 46 were significantly increased and 64 were decreased in EV GATA-4  compared to EV null . Of the 46 upregulated miRs, many were pro-angiogenetic and pro-survival factors; most notably, the let-7 family members. The tube formation was significantly increased in HUVECs treated with EV GATA-4  than in those treated with EV null . The cumulative sprout length per spheroid was also greater in EV GATA-4 -treated HUVECs than EV null -treated cells. Following Matrigel containing EVs (100μg/plug) subcutaneously transplanted into mice for 2 weeks, EV GATA-4  significantly increased the blood flow compared to EV null . Real-time imaging system recorded that EVs could be internalized by HUVECs. The expression of let-7 was significantly upregulated in HUVECs following EV GATA-4  treatment. Thrombospondin 1 (THBS1) is an anti-angiogenic gene and one of the potential target genes of let-7f. It was down-regulated in HUVEC treated with EV GATA-4  compared with that treated with EV null . To investigate the effect of transferred let-7 on angiogenesis, EVs were collected from MSCs transfected with let-7f inhibitor (anti-let-7f) or from MSCs transfected with let-7f mimic, respectively. The tube-like structure formation following different EVs treatment was positively related to the expression of let-7f in HUVECs. These results suggested that EV GATA-4  increased angiogenesis, which is associated with the transfer of pro-angiogenetic miRs to regulate their targets in HUVECs.
Abstract #4845: Prostate cancer outcome and tissue levels of metal ions
Authors: Andrey Sarafanov, Todor Todorov, Jose Centeno, Vicky Macias, Marion Gray, Weihua Gao, Wei-Min Liang, Craig Beam, Andre Kajdacsy-Balla
Journal: Cancer Research (2009)

Background: There are many studies on prostate cancer incidence and exposure to heavy metals such as cadmium, iron, selenium and zinc. Much less data is available on the possible influence of heavy metals on prostate cancer outcome. We and others have shown that cadmium, iron and zinc exposure in vitro can cause changes in cell invasion. Recently we have published an inductively coupled plasma-mass spectrometry (ICP-MS) method to reliably measure concentration of these metals in paraffin embedded archival tissues. Here we study the level of these ions in the prostate of patients with known outcome in order to address metals and disease progression. Methods: The source of tissues Cooperative Prostate Cancer Tissue Resource (CPCTR). We obtained formalin fixed paraffin embedded tissue blocks of prostatectomy samples of 40 patients with PSA recurrence, matched 1:1 (for year of surgery, race, age, Gleason grading score and stage) with tissue blocks from 40 patients without recurrence (n=80). All non-recurrence patients had more than 5-years post-prostatectomy follow-up. Case-control pairs were compared for the levels of heavy metals in areas adjacent to tumors. After deparaffinization, each tissue sample was oven-dried and divided in 5-10 µg triplicates. Internal standards were added (Y and  74 Se), digested overnight in nitric acid. ICP-MS was performed by comparing samples with standard solutions of each analyte (Cd, Fe, Zn, and Se). The association of each individual metal with prostate cancer recurrence was evaluated by Wilcoxon signed rank paired test comparing matched recurrence cases and non-recurrence control cases. Results: Patients with biochemical (PSA) recurrence of disease had 14% lower iron [95 vs. 112 parts per million (ppm); p = 0.04] and 9% lower zinc (28 vs. 35 ppm; p = 0.04) concentrations in the normal-appearing tissue immediately adjacent to prostate cancer areas. Differences in cadmium [488 vs. 439 parts per billion (ppb); 10% higher) and selenium (1676 vs. 1576 ppb; 6% higher] levels were not statistically significant in recurrence cases when compared to non-recurrences (p=0.40 and 0.21 respectively). Discussion: To the best of our knowledge this is the first study to show an association between metal tissue levels and outcomes in prostate cancer. Lower zinc in cases of worse outcome suggests this may be an area for further investigation in recurrence chemoprevention. Lower iron may be the result of iron sequestration in the reticuloendothelial system caused by aggressive cancer, rather than a factor important for prostate cancer progression, a hypothesis that needs further investigation. The lack of association of recurrence with either cadmium or selenium was an unexpected finding.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4845.
PUB052 Computer Tomography (CT) Texture Analysis as Prediction Factor in Non-Small Cell Lung Cancer Patients Undergoing Nivolumab Treatment
Authors: V. Nardone, P. Tini, E. Aldi, P. Pastina, S. Croci, L. Sebaste, G. Battaglia, S.F. Carbone, V. Ricci, M.A. Mazzei, L. Pirtoli, P. Correale
Journal: Journal of Thoracic Oncology (2017)
Bone health management in early breast cancer patients: an Italian Osteoncology Center experience
Authors: F. Recine, A. Bongiovanni, V. Fausti, L. Mercatali, N. Riva, S. Calpona, M. Faedi, A. De Vita, C. Liverani, C. Spadazzi, G. Miserocchi, F. Foca, R. Vespignani, A. Rocca, D. Amadori, T. Ibrahim
Journal: Annals of Oncology (2017)
P3.01-031 ctDNA Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non–Small-Cell Lung Cancer in Read World Setting
Authors: S. Zhang, L. Zhu, X. Chen, E. Chen, Y. Li, H. Fang, Y. Feng, Z. Qiong, H. He, S. Ma
Journal: Journal of Thoracic Oncology (2017)
P3.02-041 EGFR Amplification Mediates Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer
Authors: S. Watanabe, Y. Goto, N. Motoi, T. Kohno, J. Sato, R. Morita, S. Kanda, H. Horinouchi, Y. Fujiwara, H. Nokihara, N. Yamamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2017)